Dr. Reddy's Laboratories Limited (DRREDDY.BO)
INR 1108.55
(1.83%)
INR 1108.55
(1.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 88.27 Billion INR | 4.36% |
| 2022 | 74.06 Billion INR | 42.69% |
| 2021 | 47.74 Billion INR | 7.74% |
| 2020 | 45.7 Billion INR | -1.35% |
| 2019 | 41.78 Billion INR | 109.81% |
| 2018 | 31.86 Billion INR | 98.09% |
| 2017 | 23.73 Billion INR | -11.71% |
| 2016 | 24.54 Billion INR | -54.43% |
| 2015 | 40.17 Billion INR | 12.68% |
| 2014 | 35.15 Billion INR | 0.98% |
| 2013 | 33.13 Billion INR | 15.75% |
| 2012 | 28.13 Billion INR | 10.61% |
| 2011 | 24.69 Billion INR | 61.04% |
| 2010 | 16.87 Billion INR | -16.88% |
| 2009 | 6.58 Billion INR | -2.07% |
| 2008 | -809 Million INR | 84.75% |
| 2007 | 7.3 Billion INR | -45.65% |
| 2006 | 15.44 Billion INR | 470.48% |
| 2005 | 3.01 Billion INR | 227.66% |
| 2004 | 1.02 Billion INR | -70.86% |
| 2003 | 3.21 Billion INR | -30.45% |
| 2002 | 4.35 Billion INR | -27.7% |
| 2001 | 6 Billion INR | 143.47% |
| 2000 | 2.37 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 23.83 Billion INR | 9.56% |
| 2024 Q1 | 21.35 Billion INR | 7.25% |
| 2023 Q4 | 17.84 Billion INR | -16.18% |
| 2023 Q2 | 22.03 Billion INR | 24.79% |
| 2023 Q3 | 21.28 Billion INR | -3.4% |
| 2023 Q1 | 17.65 Billion INR | -29.39% |
| 2023 FY | - INR | 4.36% |
| 2022 Q3 | 19.24 Billion INR | -2.41% |
| 2022 Q4 | 25 Billion INR | 29.93% |
| 2022 FY | - INR | 42.69% |
| 2022 Q2 | 19.72 Billion INR | 26.82% |
| 2022 Q1 | 15.55 Billion INR | 50.79% |
| 2021 Q1 | 9.85 Billion INR | 17.6% |
| 2021 Q3 | 12.68 Billion INR | -12.27% |
| 2021 Q2 | 14.45 Billion INR | 46.61% |
| 2021 FY | - INR | 7.74% |
| 2021 Q4 | 10.31 Billion INR | -18.66% |
| 2020 Q2 | 9.87 Billion INR | -14.93% |
| 2020 Q4 | 8.38 Billion INR | -6.89% |
| 2020 Q3 | 9 Billion INR | -8.81% |
| 2020 FY | - INR | -1.35% |
| 2020 Q1 | 11.6 Billion INR | 75.42% |
| 2019 Q2 | 11.03 Billion INR | -3.28% |
| 2019 Q4 | 6.61 Billion INR | -18.1% |
| 2019 Q3 | 8.07 Billion INR | -26.8% |
| 2019 Q1 | 11.41 Billion INR | 87.17% |
| 2019 FY | - INR | 109.81% |
| 2018 FY | - INR | 98.09% |
| 2018 Q4 | 6.09 Billion INR | -3.54% |
| 2018 Q1 | 7.89 Billion INR | 198.41% |
| 2018 Q2 | 7.9 Billion INR | 0.11% |
| 2018 Q3 | 6.32 Billion INR | -20.08% |
| 2017 Q4 | 2.64 Billion INR | -47.16% |
| 2017 Q2 | 6.89 Billion INR | 97.28% |
| 2017 Q1 | 3.49 Billion INR | 11.55% |
| 2017 FY | - INR | -11.71% |
| 2017 Q3 | 5 Billion INR | -27.4% |
| 2016 FY | - INR | -54.43% |
| 2016 Q1 | 4.21 Billion INR | -16.84% |
| 2016 Q2 | 6.39 Billion INR | 51.64% |
| 2016 Q3 | 8.86 Billion INR | 38.56% |
| 2016 Q4 | 3.13 Billion INR | -64.62% |
| 2015 Q1 | 10.4 Billion INR | 70.03% |
| 2015 Q2 | 12.06 Billion INR | 15.9% |
| 2015 Q3 | 10.54 Billion INR | -12.57% |
| 2015 Q4 | 5.07 Billion INR | -51.9% |
| 2015 FY | - INR | 12.68% |
| 2014 Q2 | 8.73 Billion INR | 0.78% |
| 2014 Q3 | 9.7 Billion INR | 11.11% |
| 2014 FY | - INR | 0.98% |
| 2014 Q4 | 6.12 Billion INR | -36.92% |
| 2014 Q1 | 8.66 Billion INR | 47.95% |
| 2013 Q3 | 10.18 Billion INR | 8.43% |
| 2013 Q4 | 5.85 Billion INR | -42.51% |
| 2013 FY | - INR | 15.75% |
| 2013 Q1 | 6.09 Billion INR | -17.96% |
| 2013 Q2 | 9.39 Billion INR | 54.13% |
| 2012 Q3 | 6.35 Billion INR | -3.58% |
| 2012 Q4 | 7.42 Billion INR | 16.92% |
| 2012 Q1 | 5.47 Billion INR | -12.43% |
| 2012 FY | - INR | 10.61% |
| 2012 Q2 | 6.59 Billion INR | 20.39% |
| 2011 Q4 | 6.25 Billion INR | -17.17% |
| 2011 FY | - INR | 61.04% |
| 2011 Q2 | 5.22 Billion INR | 24.04% |
| 2011 Q1 | 4.21 Billion INR | -14.14% |
| 2011 Q3 | 7.54 Billion INR | 44.41% |
| 2010 Q3 | 4 Billion INR | -7.53% |
| 2010 Q4 | 4.9 Billion INR | 22.49% |
| 2010 FY | - INR | -16.88% |
| 2010 Q2 | 4.33 Billion INR | 58.74% |
| 2010 Q1 | 2.72 Billion INR | -13.56% |
| 2009 Q1 | 4.49 Billion INR | -21.08% |
| 2009 FY | - INR | -2.07% |
| 2009 Q4 | 3.15 Billion INR | -15.68% |
| 2009 Q3 | 3.74 Billion INR | -2.5% |
| 2009 Q2 | 3.84 Billion INR | -14.53% |
| 2008 FY | - INR | 84.75% |
| 2008 Q3 | 4.76 Billion INR | 66.79% |
| 2008 Q2 | 2.85 Billion INR | 42.93% |
| 2008 Q4 | 5.69 Billion INR | 19.46% |
| 2008 Q1 | 1.99 Billion INR | -11.49% |
| 2007 Q2 | 2.2 Billion INR | -14.89% |
| 2007 Q4 | 2.25 Billion INR | 25.92% |
| 2007 FY | - INR | -45.65% |
| 2007 Q1 | 2.58 Billion INR | -45.01% |
| 2007 Q3 | 1.79 Billion INR | -18.54% |
| 2006 Q3 | 3.08 Billion INR | -36.85% |
| 2006 Q4 | 4.7 Billion INR | 52.69% |
| 2006 Q2 | 4.87 Billion INR | 77.19% |
| 2006 Q1 | 2.75 Billion INR | 295.44% |
| 2006 FY | - INR | 470.48% |
| 2005 FY | - INR | 227.66% |
| 2005 Q1 | 585.56 Million INR | 218.69% |
| 2005 Q4 | 696.3 Million INR | 30.04% |
| 2005 Q3 | 535.46 Million INR | -39.98% |
| 2005 Q2 | 892.13 Million INR | 52.36% |
| 2004 Q3 | 107.2 Million INR | -84.95% |
| 2004 Q1 | 550.39 Million INR | 62.91% |
| 2004 FY | - INR | -70.86% |
| 2004 Q4 | -493.36 Million INR | -560.21% |
| 2004 Q2 | 712.21 Million INR | 29.4% |
| 2003 FY | - INR | -30.45% |
| 2003 Q3 | 858.98 Million INR | -34.65% |
| 2003 Q2 | 1.23 Billion INR | 8.51% |
| 2003 Q1 | 1.11 Billion INR | -14.05% |
| 2003 Q4 | 8.95 Million INR | -46.79% |
| 2002 Q3 | 886.23 Million INR | -22.09% |
| 2002 Q2 | 1.16 Billion INR | -33.92% |
| 2002 Q1 | 1.49 Billion INR | 43.73% |
| 2002 FY | - INR | -27.7% |
| 2002 Q4 | 810.12 Million INR | 44.89% |
| 2001 Q3 | 1.7 Billion INR | -31.09% |
| 2001 FY | - INR | 143.47% |
| 2001 Q1 | 746.32 Million INR | 0.0% |
| 2001 Q4 | 1.1 Billion INR | -39.48% |
| 2001 Q2 | 2.45 Billion INR | 218.04% |
| 2000 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | -817.934% |
| Aurobindo Pharma Limited | 61.78 Billion INR | -42.868% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -1186.268% |
| Granules India Limited | 8.6 Billion INR | -925.998% |
| Indoco Remedies Limited | 2.64 Billion INR | -3234.839% |
| Achyut Healthcare Limited | 524 Thousand INR | -16846274.046% |
| Ajanta Pharma Limited | 12.56 Billion INR | -602.524% |
| Alkem Laboratories Limited | 24.19 Billion INR | -264.847% |
| Alpa Laboratories Limited | 86.12 Million INR | -102393.991% |
| Brooks Laboratories Limited | 41.72 Million INR | -211448.6% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -3645.545% |
| Bajaj HealthCare Limited | 444.51 Million INR | -19758.678% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -5868.439% |
| Eris Lifesciences Limited | 6.98 Billion INR | -1163.517% |
| FDC Limited | 4.4 Billion INR | -1905.481% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | -678.185% |
| Gufic Biosciences Limited | 1.48 Billion INR | -5862.569% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -1186.501% |
| Ipca Laboratories Limited | 13.29 Billion INR | -563.747% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -27190.855% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 106806.396% |
| Lasa Supergenerics Limited | -65.08 Million INR | 135740.75% |
| Laurus Labs Limited | 8 Billion INR | -1002.611% |
| Lupin Limited | 36.96 Billion INR | -138.779% |
| Mankind Pharma Limited | 28.09 Billion INR | -214.206% |
| Medicamen Biotech Limited | 245.66 Million INR | -35833.811% |
| Medico Remedies Limited | 150.37 Million INR | -58602.071% |
| Megasoft Limited | 284.73 Million INR | -30902.947% |
| NATCO Pharma Limited | 18.79 Billion INR | -369.673% |
| Piramal Pharma Limited | 13.05 Billion INR | -576.157% |
| RPG Life Sciences Limited | 1.28 Billion INR | -6788.412% |
| Sigachi Industries Limited | 883.39 Million INR | -9892.665% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 36.201% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -1787.354% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -20415.901% |
| Unichem Laboratories Limited | 742.35 Million INR | -11791.195% |
| Wanbury Limited | 985.49 Million INR | -8857.473% |
| Windlas Biotech Limited | 781.72 Million INR | -11192.406% |
| ZIM Laboratories Limited | 462.09 Million INR | -19003.132% |
| Zydus Lifesciences Limited | 56.22 Billion INR | -57.011% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 2465.818% |
| Divi's Laboratories Limited | 25.43 Billion INR | -247.129% |
| Hester Biosciences Limited | 539.47 Million INR | -16263.282% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -2828.443% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -12833.346% |
| Bal Pharma Limited | 345.59 Million INR | -25443.126% |
| Strides Pharma Science Limited | 3.76 Billion INR | -2244.821% |
| Venus Remedies Limited | 711.8 Million INR | -12301.64% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -2158.008% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -5544.94% |
| Shilpa Medicare Limited | 2.58 Billion INR | -3310.957% |
| Aarti Drugs Limited | 3.24 Billion INR | -2617.299% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -3286.596% |
| Suven Life Sciences Limited | -992.78 Million INR | 8991.698% |
| Ind-Swift Limited | 1.06 Billion INR | -8188.219% |
| Valiant Laboratories Limited | 12.73 Million INR | -692850.781% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | -845.654% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 3228.211% |
| Themis Medicare Limited | 562.6 Million INR | -15590.349% |
| Hikal Limited | 2.69 Billion INR | -3178.88% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | -152.144% |
| Sequent Scientific Limited | 549.8 Million INR | -15955.838% |
| Novartis India Limited | 1.26 Billion INR | -6854.621% |
| Wockhardt Limited | 1.08 Billion INR | -8073.611% |
| Jubilant Pharmova Limited | 8 Billion INR | -1002.611% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -675715.342% |
| Neuland Laboratories Limited | 4.74 Billion INR | -1759.132% |
| Morepen Laboratories Limited | 1.72 Billion INR | -5014.563% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -30612.36% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -50358.427% |